Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 6/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9891755 | 0.82 | LIPE (0.44) | HCRTR1HCRTR2POLBL3MBTL1LIPE | |
| SCHEMBL9892984 | 0.81 | POLB (0.54) | POLBL3MBTL1TDP1MEN1CYP1A2 | |
| SCHEMBL16480454 | 0.80 | NPC1 (0.49) | L3MBTL1ABL1MAPTCYP2C9CYP2C19 | |
| SCHEMBL16480425 | 0.79 | HRH3 (0.43) | L3MBTL1HRH3ABL1TDP1MAPT | |
| SCHEMBL9107773 | 0.79 | TDP1 (0.45) | HCRTR1HCRTR2POLBLIPEEPHX2 | |
| SCHEMBL9107780 | 0.79 | TDP1 (0.45) | HCRTR1HCRTR2POLBLIPEEPHX2 | |
| SCHEMBL14155611 | 0.78 | HDAC1 (0.55) | HCRTR1HCRTR2LIPEMEN1KMT2A | |
| SCHEMBL16480393 | 0.78 | TDP1 (0.47) | POLBABL1TDP1MEN1CYP1A2 | |
| SCHEMBL11113574 | 0.77 | GLA (0.59) | POLBL3MBTL1HRH3ABL1TDP1 | |
| SCHEMBL4636834 | 0.76 | GAA (0.46) | POLBABL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2384320-B1 | PYRROLIDINE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INT (DE) | 2015-03-04 | — | — | EP | disclosed |
| US-8629157-B2 | Pyrrolidine compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | HCRTR1 221/4885HCRTR2 142/4885POLB 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.